Provider review
NovoCare Pharmacy review
The manufacturer own pharmacy — it defines the month, and dates its own price change.
Two disclosures almost nothing else here makes: the billing unit is defined as one box, and the date the price rises is published along with the figure it rises to.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
NovoCare Pharmacy
$149/mo self-pay Wegovy at 1.5 mg or 4 mg, $199 after Aug 31 2026
- Vs median
- $20/mo below the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Not a compounded product
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
This is the manufacturer selling directly rather than a telehealth company reselling a compounded copy, and it behaves differently in ways worth naming precisely. It defines what a month is — one box — which is the single disclosure most sellers reviewed on this site avoid, several of them by quietly billing four weeks and calling it a month. And it publishes the date its own price rises together with the figure it rises to, so a reader budgeting a year is working from stated facts rather than guessing. Both are the exact opposite of the pattern this site keeps documenting, and they deserve credit. What this is not is cheap or simple. The lowest advertised figure applies with commercial insurance and is capped, which makes it a copay outcome rather than a price — what you actually pay depends on coverage you have to go and check. Self-pay starts higher and varies by dose, with only two doses carrying the entry figure. Against the compounded sellers reviewed here it is substantially dearer, and that is the honest comparison to make: this is the approved product from the company that makes it, which is a different thing from a compounded preparation at a fraction of the price. Worth the difference to some readers and not to others.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want the approved product from the manufacturer rather than a compounded preparation.
- You want the billing unit defined rather than assumed — a month here is one box.
- You want to know in advance when the price changes and what it becomes.
Look elsewhere if
- You are price-shopping. This is substantially dearer than the compounded routes here.
- You are quoting the lowest figure. It is an insurance copay outcome with a capped saving.
- You want tirzepatide. This pharmacy carries the semaglutide product.
What it actually costs
Price as published
★★ Novo Nordisk's own direct pharmacy for Wegovy rather than a telehealth reseller. With commercial insurance, "pay as little as $25 per month", subject to a maximum saving of $100 a month · self-pay "starting at $149 per month" for the 1.5 mg or 4 mg doses · ★★★ it DEFINES its unit — "month defined as 1 box" — which is the disclosure five sellers on this site avoid by calling four weeks a month · ★★ and it dates its own price change: the 4 mg offer runs "only available until August 31, 2026, then $199 per month for 4 mg", so the reader is told in advance what the figure becomes and when · self-pay pricing varies by dose and only two doses carry the $149 figure · the $25 rate depends on commercial insurance and a capped saving, so it is a copay outcome rather than a price
- Vs median
- $20/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. The manufacturer own pharmacy for brand-name Wegovy rather than a compounded reseller. ★★ It DEFINES its billing unit — "month defined as 1 box" — and publishes the date its own price changes. No low-dose product exists; the approved product is sold at its label doses. Tirzepatide is not carried.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Billed separately
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- Defines a month as one box rather than leaving the billing cycle to be assumed.
- Publishes the date its own price changes and the figure it changes to.
- It is the approved product direct from the manufacturer, not a compounded copy.
Pharmacy, labs and oversight
NovoCare Pharmacy dispenses through a Not applicable — brand-name Wegovy from the manufacturer's own pharmacy facility. No bloodwork is required before you start. A clinician review is billed separately.
Transparency check
3 of 4 published openly
What NovoCare Pharmacy publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
This is the manufacturer selling directly rather than a telehealth company reselling a compounded copy, and it behaves differently in ways worth naming. It defines what a month is — one box — which is the single disclosure most sellers reviewed here avoid, and it publishes the date its own price rises along with the figure it rises to, so a reader budgeting a year is not guessing. Both of those are the opposite of the pattern this site keeps documenting. What it is not is cheap or simple. The headline figure with commercial insurance is a copay outcome rather than a price: it depends on your plan and it is capped, so what you actually pay is a function of coverage you have to check yourself. Self-pay starts higher and varies by dose, with only two doses carrying the entry figure. Set against compounded sellers here it is dearer, and that is the honest comparison — this is the approved product from the company that makes it, which is a different thing from a compounded preparation at a third of the price, and worth the difference to some readers and not to others.
The honest cons
The lowest advertised figure is an insurance copay outcome with a capped saving, not a price.
- Self-pay pricing varies by dose, and only two doses carry the entry figure.
- Substantially dearer than the compounded routes reviewed elsewhere here.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
NovoCare Pharmacy is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#193 of 373
Ordered with the companies that pay us first, and NovoCare Pharmacy is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.